scholarly journals First report of the genomic characterization of rubella viruses circulating in Cameroon

2019 ◽  
Vol 91 (6) ◽  
pp. 928-934
Author(s):  
Franck‐Martin Obam Mekanda ◽  
Chavely Gwladys Monamele ◽  
Frédy Brice Simo Nemg ◽  
Francine Berlange Sado Yousseu ◽  
Dieudonné Ndjonka ◽  
...  
Keyword(s):  
First Report ◽  
Genomic Characterization

scholarly journals Genomic characterization of XDR Klebsiella pneumoniae ST147 co-resistant to carbapenem and colistin – The first report in India

2020 ◽  
Vol 22 ◽  
pp. 54-56
Author(s):  
Suchanda Dey ◽  
Mahendra Gaur ◽  
Rajesh Kumar Sahoo ◽  
Aradhana Das ◽  
Bhawana Jain ◽  
...  
Keyword(s):  
Klebsiella Pneumoniae ◽  
First Report ◽  
Genomic Characterization

Genomic characterization of γ-terpinene synthase from Thymus caespititius

Planta Medica ◽  
2011 ◽  
Vol 77 (12) ◽  
Author(s):  
AS Lima ◽  
B Lukas ◽  
J Novak ◽  
AC Figueiredo ◽  
LG Pedro ◽  
...  
Keyword(s):  
Genomic Characterization

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation

2020 ◽  
Vol 20 (7) ◽  
pp. 490-500 ◽  
Author(s):  
Justin S. Becker ◽  
Amir T. Fathi
Keyword(s):  
Genome Structure ◽  
Cellular Metabolism ◽  
Standard Of Care ◽  
Competitive Inhibitor ◽  
Driver Mutations ◽  
New Class ◽  
Regulatory Enzymes ◽  
Idh Mutations ◽  
Genomic Characterization

The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms in cancer synthesize an abnormal metabolite, 2- hydroxyglutarate, that in turn acts as a competitive inhibitor of multiple gene regulatory enzymes. As a result, leukemic IDH mutations cause changes in genome structure and gene activity, culminating in an arrest of normal myeloid differentiation. These discoveries have motivated the development of a new class of selective small molecules with the ability to inhibit the mutant IDH enzymes while sparing normal cellular metabolism. These agents have shown promising anti-leukemic activity in animal models and early clinical trials, and are now entering Phase 3 study. This review will focus on the growing preclinical and clinical data evaluating IDH inhibitors for the treatment of IDH-mutated AML. These data suggest that inducing cellular differentiation is central to the mechanism of clinical efficacy for IDH inhibitors, while also mediating toxicity for patients who experience IDH Differentiation Syndrome. Ongoing trials are studying the efficacy of IDH inhibitors in combination with other AML therapies, both to evaluate potential synergistic combinations as well as to identify the appropriate place for IDH inhibitors within existing standard-of-care regimens.

Sign in / Sign up

Export Citation Format

Share Document